November 14, 2017 03:28 PM EST

Mirati bails on lead drug, shifts focus to I/O program

Brittany Meiling

The stock is sinking for San Diego biotech Mirati Therapeutics $MRTX following news that the company is siphoning resources from its lead drug to fund …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mirati bails on lead drug, shifts focus to I/O program

Brittany Meiling

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Here's what today's Fed rate cut means for biotech, pharma and venture capital

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development

Mi­rati bails on lead drug, shifts fo­cus to I/O pro­gram

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Mirati bails on lead drug, shifts focus to I/O program